Press Releases

 

General

  Date Title and Summary View
Nov 20, 2017
Collaboration with University of Oxford to Execute a Clinical Trial Using Focused Ultrasound and ThermoDox® for Primary and Metastatic Liver Cancer Presentation of TARDOX Study Phase I Findings at the Upcoming RSNA 2017 Annual Meeting First Ever Study Evaluating ThermoDox® with Focused Ultrasound in Humans LAWRENCEVILLE, N.J., Nov....
Nov 14, 2017
Recent Minimally Dilutive Financings Substantially Strengthen Balance Sheet and Provide Runway to Significant Clinical Milestones for ThermoDox® and GEN-1 Clinical Programs Company to Hold Conference Call on Tuesday, November 14, 2017 at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CL...
Nov 13, 2017
Expert Advisory Board Endorses Randomized Phase I/II Trial in Newly Diagnosed Stage III and IV Ovarian Cancer GEN-1 Immunotherapy to Enter Phase I/II Clinical Study in the First Half of 2018 Following a Phase IB Trial Demonstrating 100% Disease Control, 86% Objective Response Rate and 86% R0 & R1 Surgical Resection Rate in All Patients Treated...
Nov 13, 2017
Expert Advisory Board Endorses Randomized Phase I/II Trial in Newly Diagnosed Stage III and IV Ovarian Cancer GEN-1 Immunotherapy to Enter Phase I/II Clinical Study in the First Half of 2018 Following a Phase IB Trial Demonstrating 100% Disease Control, 86% Objective Response Rate and 86% R0 & R1 Surgical Resection Rate in All Patients Treated...
Nov 7, 2017
LAWRENCEVILLE, N.J., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended September 30, 2017 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of...
Oct 27, 2017
LAWRENCEVILLE, N.J., Oct. 27, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (the "Company") (NASDAQ:CLSN) today announced the pricing of an underwritten offering of 2,640,000 shares of its common stock and warrants to purchase up to 1,320,000 shares of common stock at an offering price of $2.50 per share and related warrants. Each share of common ...
Oct 18, 2017
LAWRENCEVILLE, N.J., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today provided a summary of GEN-1 immunotherapy-related presentations made during the Company's Research and Development (R&D) Day held on Thursday, October 12, 2017.  This summary is intended to provide easy access to p...
Oct 17, 2017
LAWRENCEVILLE, N.J., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology development company, today provided a summary of ThermoDox® related presentations made during the Company's Research and Development (R&D) Day held on Thursday, October 12, 2017.  This summary is intended to provide easy access to pertinent,...
Oct 16, 2017
80+ Month Overall Survival (HR = 0.63, Pvalue = 0.02) Discussed in the 285 Patient Sub-group Treated with ThermoDox® plus Standardized Radiofrequency Ablation (sRFA) Ongoing Phase III OPTIMA Study to Confirm Hypothesis that the Combination of Standardized Radiofrequency Ablation Plus ThermoDox® May Substantially Increase Survival of ...
Oct 12, 2017
LAWRENCEVILLE, N.J., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology development company, today announced that it will host a Research and Development (R&D) Day for investors and analysts on Thursday, October 12, 2017.  The event will take place from 4:00 to 6:00 p.m. Eastern Time in New York City, and will be sim...
Page:
1
... NextLast
= add release to Briefcase
Share This